Floatz Rating
D30/100
Confidence
Indicative
Sponsor
Xijing Hospital
Modality
UNKNOWN
Development Phase
N/A
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07014254CT.gov Therapeutic Study of 177Lu-CTR-FAPI in Advanced Metastatic Digestive Malignancies | — | Not Yet Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Neuroendocrine Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| 177lu-ctr-fapi (this asset) | Xijing Hospital | N/A | D · 30 |
| Fluorouracilum | ITM Solucin GmbH | P3 | BB |
| Cabozantinib | Fox Chase Cancer Center | P3 | BB |
| Irinotecan | First Affiliated Hospital Xi'an Jiaotong University | P4 | BB |
| Oxodotreotide | Fundación de investigación HM | P3 | BB |
| Everolimus | Exelixis | P3 | BB |
| Surufatinib | Shanghai Changzheng Hospital | P3 | BB |
| Carboplatin | First Affiliated Hospital Xi'an Jiaotong University | P4 | B |
| L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R*,R*))- | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | P4 | B |
+42 more in the Neuroendocrine Neoplasm cohort
Other indications for 177lu-ctr-fapi
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metastatic Neoplasm | — | Early P1 | CC · 43 |
| Pancreatic Neoplasm | — | Early P1 | C · 33 |
| Pancreatic Ductal Adenocarcinoma | — | N/A | D · 30 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. 177lu-ctr-fapi in Neuroendocrine Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/177lu-ctr-fapi-neuroendocrine-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →